SOLVADYS^® is Curacle's proprietary oral small-molecule platform,
enabling the development of first-in-class therapies targeting endothelial dysfunction.

It is built on three core strengths:

• 1

  Multi-phenotypic screening – Human endothelial cell–based assays that capture diverse pathological changes,

• 2

  In vivo efficacy testing – Validation of therapeutic effects in disease models, and

• 3

  Pathomechanistic validation – Elucidation of mechanisms and confirmation of clinical applicability.

CU06-1004 is the world's first Endothelial Dysfunction Blocker, discovered and developed through Curacle’s SOLVADYS ^® platform.
With its innovative mechanism of protecting endothelial cells and restoring their function, CU06-1004 has demonstrated therapeutic efficacy in more than 10 disease models including Diabetic Macular Edema (DME), Inflammatory Bowel Disease (IBD), neurodegenerative diseases, Immuno-Oncology, etc.
— with results published in peer-reviewed journals. Designated with the INN Rivasterat, the molecule has now successfully completed a Phase 2a trial in DME and is advancing as a next-generation oral therapy.